Malaysia Biotech Industry Lags In Expected Growth
This article was originally published in PharmAsia News
Malaysia's experiment in building a biotechnology industry is lagging behind initial goals as the government approaches the second five-year phase set to begin in 2011. Plans call for the biotech industry to more than double its share of the economy to 2.5 percent within the 2011-2016 period. Since the National Biotechnology Policy was adopted in 2005, the biotech industry has grown only enough to constitute 1 percent of gross domestic product. The head of the government's Malaysia Biotechnology Corp said the nation needs more cooperation between researchers and industry players. (Click here for more
You may also be interested in...
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.
On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.